Literature DB >> 27308548

Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations.

Benjamin G Bitler1, Katherine M Aird1, Rugang Zhang1.   

Abstract

The components of the Switch/Sucrose non-fermentable (SWI/SNF) complex are mutated in approximately 20% of human cancers. The A/T-rich interacting domain 1A (ARID1A) subunit has one of the highest mutation rates. Most notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas (OCCCs). We reported that inhibition of enhancer of zeste homology 2 (EZH2) is synthetically lethal in ARID1A-mutated OCCC.

Entities:  

Keywords:  ARID1A; EZH2; SWI/SNF chromatin-remodeling complex; ovarian cancer; synthetic lethality

Year:  2015        PMID： 27308548      PMCID： PMC4845188          DOI： 10.1080/23723556.2015.1032476

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

2.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

3.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

Authors:  Sarah K Knutson; Natalie M Warholic; Tim J Wigle; Christine R Klaus; Christina J Allain; Alejandra Raimondi; Margaret Porter Scott; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock; Kevin W Kuntz; Heike Keilhack
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

4.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

5.  Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.

Authors:  Boris G Wilson; Xi Wang; Xiaohua Shen; Elizabeth S McKenna; Madeleine E Lemieux; Yoon-Jae Cho; Edward C Koellhoffer; Scott L Pomeroy; Stuart H Orkin; Charles W M Roberts
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

6.  ARID1A mutations in endometriosis-associated ovarian carcinomas.

Authors:  Kimberly C Wiegand; Sohrab P Shah; Osama M Al-Agha; Yongjun Zhao; Kane Tse; Thomas Zeng; Janine Senz; Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Alireza Heravi-Moussavi; Ryan Giuliany; Christine Chow; John Fee; Abdalnasser Zayed; Leah Prentice; Nataliya Melnyk; Gulisa Turashvili; Allen D Delaney; Jason Madore; Stephen Yip; Andrew W McPherson; Gavin Ha; Lynda Bell; Sian Fereday; Angela Tam; Laura Galletta; Patricia N Tonin; Diane Provencher; Dianne Miller; Steven J M Jones; Richard A Moore; Gregg B Morin; Arusha Oloumi; Niki Boyd; Samuel A Aparicio; Ie-Ming Shih; Anne-Marie Mes-Masson; David D Bowtell; Martin Hirst; Blake Gilks; Marco A Marra; David G Huntsman
Journal:  N Engl J Med       Date:  2010-09-08       Impact factor: 91.245

7.  Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors.

Authors:  Xiaomei Wang; Norman G Nagl; Stephen Flowers; Daniel Zweitzig; Peter B Dallas; Elizabeth Moran
Journal:  Int J Cancer       Date:  2004-11-20       Impact factor: 7.396

8.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.

Authors:  Benjamin G Bitler; Katherine M Aird; Azat Garipov; Hua Li; Michael Amatangelo; Andrew V Kossenkov; David C Schultz; Qin Liu; Ie-Ming Shih; Jose R Conejo-Garcia; David W Speicher; Rugang Zhang
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

9.  Discovery and saturation analysis of cancer genes across 21 tumour types.

Authors:  Michael S Lawrence; Petar Stojanov; Craig H Mermel; James T Robinson; Levi A Garraway; Todd R Golub; Matthew Meyerson; Stacey B Gabriel; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2014-01-05       Impact factor: 49.962

10.  Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.

Authors:  Ronald L Chandler; Jeffrey S Damrauer; Jesse R Raab; Jonathan C Schisler; Matthew D Wilkerson; John P Didion; Joshua Starmer; Daniel Serber; Della Yee; Jessie Xiong; David B Darr; Fernando Pardo-Manuel de Villena; William Y Kim; Terry Magnuson
Journal:  Nat Commun       Date:  2015-01-27       Impact factor: 14.919
  10 in total
  7 in total

1.  Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.

Authors:  Jessica D Lang; William P D Hendricks; Krystal A Orlando; Hongwei Yin; Jeffrey Kiefer; Pilar Ramos; Ritin Sharma; Patrick Pirrotte; Elizabeth A Raupach; Chris Sereduk; Nanyun Tang; Winnie S Liang; Megan Washington; Salvatore J Facista; Victoria L Zismann; Emily M Cousins; Michael B Major; Yemin Wang; Anthony N Karnezis; Aleksandar Sekulic; Ralf Hass; Barbara C Vanderhyden; Praveen Nair; Bernard E Weissman; David G Huntsman; Jeffrey M Trent
Journal:  Clin Cancer Res       Date:  2018-02-09       Impact factor: 12.531

2.  An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Authors:  Kate E Oliver; William E Brady; Michael Birrer; David M Gershenson; Gini Fleming; Larry J Copeland; Krishnansu Tewari; Peter A Argenta; Robert S Mannel; Angeles Alvarez Secord; Jean-Marie Stephan; David G Mutch; Frederick B Stehman; Franco M Muggia; Peter G Rose; Deborah K Armstrong; Michael A Bookman; Robert A Burger; John H Farley
Journal:  Gynecol Oncol       Date:  2017-08-12       Impact factor: 5.482

3.  Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.

Authors:  Swathi Ramakrishnan; Victoria Granger; Monika Rak; Qiang Hu; Kristopher Attwood; Lanni Aquila; Nithya Krishnan; Rafal Osiecki; Gissou Azabdaftari; Khurshid Guru; Gurkamal Chatta; Geraldine Gueron; Lacey McNally; Joyce Ohm; Jianmin Wang; Anna Woloszynska
Journal:  Cell Death Differ       Date:  2019-01-28       Impact factor: 15.828

Review 4.  Endometriosis and ovarian cancer risk, an epigenetic connection.

Authors:  Sarah Brunty; Brenda Mitchell; Nadim Bou-Zgheib; Nalini Santanam
Journal:  Ann Transl Med       Date:  2020-12

Review 5.  Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.

Authors:  Eleftherios P Samartzis; S Intidhar Labidi-Galy; Michele Moschetta; Mario Uccello; Dimitrios R Kalaitzopoulos; J Alejandro Perez-Fidalgo; Stergios Boussios
Journal:  Ann Transl Med       Date:  2020-12

6.  ARID1A promotes genomic stability through protecting telomere cohesion.

Authors:  Bo Zhao; Jianhuang Lin; Lijie Rong; Shuai Wu; Zhong Deng; Nail Fatkhutdinov; Joseph Zundell; Takeshi Fukumoto; Qin Liu; Andrew Kossenkov; Stephanie Jean; Mark G Cadungog; Mark E Borowsky; Ronny Drapkin; Paul M Lieberman; Cory T Abate-Shen; Rugang Zhang
Journal:  Nat Commun       Date:  2019-09-06       Impact factor: 14.919

7.  Peritoneal Modulators of EZH2-miR-155 Cross-Talk in Endometriosis.

Authors:  Sarah Brunty; Kristeena Ray Wright; Brenda Mitchell; Nalini Santanam
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.